Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation’s leading independent specialty pharmacy, recently declared the appointment of Ben Wolin as independent Lead Director, effective right away. Mr. Wolin, a member of the Company’s Nominating and Corporate Governance Committee and its Audit Committee, was designated to the newly created position by the Company’s independent directors.
Phil Hagerman, chairman and CEO of Diplomat, commented, “The appointment of a lead director is a continuation of Diplomat’s growing corporate governance practices. Ben possesses the extensive healthcare experience and broad perspective critical to oversee the efficient running of Diplomat’s governance structure while upholding the interests of our shareholders.” “I am honored to be designated by the Company’s independent directors to this new position,” said Mr. Wolin. “I understand the important role that a lead director can play in ensuring that a board appropriately monitors the administration team while providing strong independent leadership and planned guidance. I look forward to continuing to work with the Board to further enhance value for all Diplomat shareholders.”